برنامج تطوير مهنة الصيدلة - PPDPROGRAM

➡️Trelegy Ellipta (fluticasone furoate, umeclidinium and vilanterol) Inhalation Powder Date of Approval: September 18, 2017 Company: GlaxoSmithKline Treatment for: COPD, Asthma, Maintenance Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) is an inhaled corticosteroid, long-acting muscarinic antagonist (LAMA), and long-acting beta2-adrenergic agonist (LABA) combination indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD), and the maintenance treatment of asthma in patients aged 18 years and older. https://t.me/ppdprogram

➡️Solosec (secnidazole) Oral Granules Date of Approval: September 15, 2017 Company: Lupin Pharmaceuticals, Inc. Treatment for: Bacterial Vaginosis, Trichomoniasis Solosec (secnidazole) is a nitroimidazole antimicrobial for use as a single-dose oral therapy in the treatment of bacterial vaginosis (BV) and trichomoniasis. https://t.me/ppdprogram

➡️KedRAB (rabies immunoglobulin human) Injection Date of Approval: August 23, 2017 Company: Kamada Ltd. and Kedrion S.p.A. Treatment for: Rabies Prophylaxis KedRAB [rabies immunoglobulin (human)] is a human plasma derived anti-rabies immunoglobulin indicated for post-exposure prophylaxis (PEP) of rabies infection. https://t.me/ppdprogram

➡️CaroSpir (spironolactone) Oral Suspension Date of Approval: August 4, 2017 Company: CMP Pharma, Inc. Treatment for: Heart Failure, Edema, High Blood Pressure CaroSpir (spironolactone) is an oral suspension formulation of the potassium-sparing diuretic spironolactone indicated for the treatment of heart failure, management of edema, and for use as an add-on therapy in the treatment of hypertension. https://t.me/ppdprogram

➡️Vabomere (meropenem and vaborbactam) Injection - formerly Carbavance Date of Approval: August 29, 2017 Company: The Medicines Company Treatment for: Urinary Tract Infection Vabomere (meropenem and vaborbactam) is a carbapenem and beta-lactamase inhibitor combination for the treatment of complicated urinary tract infections (cUTIs). https://t.me/ppdprogram

➡️(benznidazole) Tablets Date of Approval: August 29, 2017 Company: Chemo Research, S. L. Treatment for: Chagas Disease Benznidazole is an antiprotozoal indicated for the treatment of Chagas disease, or American trypanosomiasis, a parasitic infection caused by Trypanosoma cruzi. https://t.me/ppdprogram

➡️Endari (L-glutamine) Oral Powder Date of Approval: July 7, 2017 Company: Emmaus Life Sciences Inc. Treatment for: Anemia, Sickle Cell Endari (L-glutamine) is orally-administered pharmaceutical grade L-glutamine (PGLG), an amino acid formulation to relieve pain, swelling and other complications of sickle cell anemia. https://t.me/ppdprogram

➡️Baxdela (delafloxacin) Tablets and Injection Date of Approval: June 19, 2017 Company: Melinta Therapeutics Treatment for: Skin and Structure Infection, Pneumonia Baxdela (delafloxacin) is a fluoroquinolone antibacterial indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP) caused by designated susceptible bacteria. https://t.me/ppdprogram

➡️Symjepi (epinephrine) Injection Date of Approval: June 15, 2017 Company: Adamis Pharmaceuticals Corporation Treatment for: Allergic Reactions Symjepi (epinephrine) is a non-selective alpha and betaadrenergic receptor agonist in a single-dose, pre-filled syringe for use the emergency treatment of allergic reactions (Type I) including anaphylaxis. https://t.me/ppdprogram

➡️Rebinyn (coagulation factor IX (recombinant), glycopegylated) Injection Date of Approval: May 31, 2017 Company: Novo Nordisk Treatment for: Hemophilia B Rebinyn (coagulation factor IX (recombinant), glycopegylated is an extended-half-life recombinant DNA-derived coagulation factor IX concentrate for the treatment and control of bleeding episodes in patients with hemophilia B. https://t.me/ppdprogram

➡️Odactra (house dust mite allergen extract) Sublingual Tablets Date of Approval: March 1, 2017 Company: ALK-Abelló A/S Treatment for: House Dust Mite Allergies Odactra (house dust mite allergen extract) is a sublingual allergy immunotherapy (SLIT) tablet indicated as immunotherapy for house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis. https://t.me/ppdprogram

➡️Qtern (dapagliflozin and saxagliptin) Tablets Date of Approval: February 27, 2017 Company: AstraZeneca Treatment for: Diabetes, Type 2 Qtern (dapagliflozin and saxagliptin) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor and dipeptidyl peptidase-4 (DPP4) inhibitor fixed-dose combination for the treatment of adult patients with type 2 diabetes. https://t.me/ppdprogram

➡️Emflaza (deflazacort) Tablets and Oral Suspension Date of Approval: February 9, 2017 Company: PTC Therapeutics, Inc. Treatment for: Duchenne Muscular Dystrophy Emflaza (deflazacort) is a glucocorticoid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older. https://t.me/ppdprogram

➡️Parsabiv (etelcalcetide) Injection Date of Approval: February 7, 2017 Company: Amgen Inc. Treatment for: Secondary Hyperparathyroidism Parsabiv (etelcalcetide) is a calcium-sensing receptor agonist indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis. https://t.me/ppdprogram

➡️ArmonAir RespiClick (fluticasone propionate) Inhalation Powder Date of Approval: January 27, 2017 Company: Teva Pharmaceutical Industries Ltd. Treatment for: Asthma, Maintenance ArmonAir RespiClick (fluticasone propionate) is an inhaled corticosteroid in a breath-activated, multi-dose dry powder inhaler formulation for the treatment of asthma. https://t.me/ppdprogram

➡️AirDuo RespiClick (fluticasone propionate and salmeterol) Inhalation Powder Date of Approval: January 27, 2017 Company: Teva Pharmaceutical Industries Ltd. Treatment for: Asthma, Maintenance AirDuo RespiClick (fluticasone propionate and salmeterol) is a corticosteroid and long-acting beta2-adrenergic agonist (LABA) combination in a breath-activated, multi-dose dry powder inhaler formulation for the treatment of asthma. https://t.me/ppdprogram

➡️Rhofade (oxymetazoline hydrochloride) Cream Date of Approval: January 18, 2017 Company: Allergan plc Treatment for: Rosacea Rhofade (oxymetazoline hydrochloride) is a topical alpha1A adrenoceptor agonist vasoconstrictor for the treatment of persistent facial erythema associated with rosacea in adults. https://t.me/ppdprogram

➡️Vaxelis (diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus, haemophilus b conjugate [meningococcal protein conjugate] and hepatitis B [recombinant] vaccine) Suspension for Intramuscular Injection Date of Approval: December 21, 2018 Company: Merck and Sanofi Treatment for: Diphtheria Prophylaxis, Tetanus Prophylaxis, Pertussis Prophylaxis, Poliomyelitis Prophylaxis, Hepatitis B Prevention, Haemophilus influenzae Prophylaxis Vaxelis is a hexavalent combination vaccine indicated for active immunization to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenzae type b in children from 6 weeks through 4 years of age (prior to the 5th birthday). https://t.me/ppdprogram

➡️ProAir Digihaler (albuterol sulfate) Inhalation Powder Date of Approval: December 21, 2018 Company: Teva Pharmaceutical Industries Ltd. Treatment for: Bronchospasm Prophylaxis, Asthma, COPD ProAir Digihaler (albuterol sulfate) is a beta2-adrenergic agonist indicated for the treatment or prevention of bronchospasm in patients with reversible obstructive airway disease, and the prevention of exercise-induced bronchospasm. https://t.me/ppdprogram

➡️Inbrija (levodopa) Inhalation Powder Date of Approval: December 21, 2018 Company: Acorda Therapeutics, Inc. Treatment for: Parkinson's Disease Inbrija (levodopa) is an oral inhalation formulation of the approved drug levodopa for the treatment of OFF episodes in people with Parkinson’s disease taking a carbidopa/levodopa regimen. https://t.me/ppdprogram